Tenax Therapeutics (TENX) Income from Continuing Operations (2016)
Historic Income from Continuing Operations for Tenax Therapeutics (TENX) over the last 6 years, with Q4 2016 value amounting to -$34.3 million.
- Tenax Therapeutics' Income from Continuing Operations fell 18307.41% to -$34.3 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$55.5 million, marking a year-over-year increase of 5858.27%. This contributed to the annual value of -$17.6 million for FY2024, which is 12643.43% down from last year.
- Per Tenax Therapeutics' latest filing, its Income from Continuing Operations stood at -$34.3 million for Q4 2016, which was down 18307.41% from -$4.5 million recorded in Q3 2016.
- Tenax Therapeutics' 5-year Income from Continuing Operations high stood at $108.6 million for Q2 2012, and its period low was -$118.0 million during Q2 2013.
- Moreover, its 4-year median value for Income from Continuing Operations was -$4.6 million (2016), whereas its average is -$8.0 million.
- The largest annual percentage gain for Tenax Therapeutics' Income from Continuing Operations in the last 5 years was 371057.81% (2012), contrasted with its biggest fall of 35790.41% (2012).
- Over the past 4 years, Tenax Therapeutics' Income from Continuing Operations (Quarter) stood at -$1.6 million in 2012, then plummeted by 7512.64% to -$118.0 million in 2013, then skyrocketed by 89.74% to -$12.1 million in 2015, then tumbled by 183.07% to -$34.3 million in 2016.
- Its Income from Continuing Operations stands at -$34.3 million for Q4 2016, versus -$4.5 million for Q3 2016 and -$4.7 million for Q2 2016.